Detalhe da pesquisa
1.
Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial.
Int J Cancer
; 153(4): 815-825, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37155342
2.
Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
Anticancer Drugs
; 34(10): 1146-1150, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36728908
3.
HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma.
Oncologist
; 26(9): 717-721, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33896090
4.
Metastatic Low-Grade Sarcoma with CARS-ALK Fusion Dramatically Responded to Multiple ALK Tyrosine Kinase Inhibitors: A Case Report with Comprehensive Genomic Analysis.
Oncologist
; 26(4): e524-e529, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32997436
5.
Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report.
BMC Cancer
; 18(1): 206, 2018 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29463236
6.
New clinical trial design in precision medicine: discovery, development and direction.
Signal Transduct Target Ther
; 9(1): 57, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38438349
7.
Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).
Front Oncol
; 13: 860711, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36910668
8.
[Clinical observation of prophylactic lactulose for prevention of oral morphine-induced constipation].
Zhonghua Yi Xue Za Zhi
; 92(42): 2968-71, 2012 Nov 13.
Artigo
em Chinês
| MEDLINE | ID: mdl-23328286
9.
Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC.
Lung Cancer
; 170: 91-97, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35728482
10.
Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial.
Eur J Cancer
; 163: 152-162, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074651
11.
Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8+T cells.
Cell Oncol (Dordr)
; 45(6): 1297-1309, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36260222
12.
Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy.
Front Oncol
; 12: 1007146, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36686739
13.
Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer.
Oncoimmunology
; 10(1): 1929727, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34350061
14.
Primary squamous cell carcinoma of pancreas: a population-based study.
Gland Surg
; 10(3): 1029-1037, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33842247
15.
Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma.
Transl Lung Cancer Res
; 10(7): 3236-3250, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34430361
16.
Response to Pyrotinib in a Chinese Patient with Bone-Metastatic Scrotal Paget's Disease Harboring Triple Uncommon HER2 Mutation: A Case Report.
Onco Targets Ther
; 13: 6289-6293, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32753879
17.
The effect of liver metastasis on efficacy of immunotherapy plus chemotherapy in advanced lung cancer.
Crit Rev Oncol Hematol
; 147: 102893, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32065969
18.
Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types.
Ann Transl Med
; 8(14): 860, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32793704
19.
The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base.
J Thorac Dis
; 11(11): 4507-4515, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31903239
20.
Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy.
J Immunother Cancer
; 12(4)2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38631713